Literature DB >> 8938265

Insulin receptor mRNA in the substantia nigra in Parkinson's disease.

M Takahashi1, T Yamada, I Tooyama, I Moroo, H Kimura, T Yamamoto, H Okada.   

Abstract

Neurotrophic effects resulting from the insulin/insulin receptor system have been recognized as important in determining the etiological basis of neurodegenerative disorders. In Parkinson's disease, selective neuronal loss in the substantia nigra is accompanied by decreased immunoreactivity of the insulin receptor as determined using immunohistochemical studies. We performed semiquantitative mRNA analysis by reverse transcription-polymerase chain reaction (RT-PCR) using specific primers for human insulin receptor exon 22, which encodes a region of the beta subunit of the receptor serving as a tyrosine kinase domain. The relative levels of mRNA in the substantia nigra from Parkinson's brain tissues showed a marked depression compared with those of normal controls. Further investigations are needed to decide whether this is a primary, disease-specific alteration of gene expression or merely a secondary process.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938265     DOI: 10.1016/0304-3940(96)12357-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  42 in total

Review 1.  Tissue-specific targeting of the insulin receptor gene.

Authors:  Rohit N Kulkarni; Terumasa Okada
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

Review 2.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 3.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 4.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

5.  Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  J K Morris; H Zhang; A A Gupte; G L Bomhoff; J A Stanford; P C Geiger
Journal:  Brain Res       Date:  2008-09-11       Impact factor: 3.252

6.  Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection.

Authors:  Shiek Ssj Ahmed; Winkins Santosh; Suresh Kumar; Hema T Thanka Christlet
Journal:  J Biomed Sci       Date:  2009-07-13       Impact factor: 8.410

Review 7.  Insulin receptor signaling in the development of neuronal structure and function.

Authors:  Shu-Ling Chiu; Hollis T Cline
Journal:  Neural Dev       Date:  2010-03-15       Impact factor: 3.842

Review 8.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

9.  Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease.

Authors:  Corinne Lautier; Stefano Goldwurm; Alexandra Dürr; Barbara Giovannone; William G Tsiaras; Gianni Pezzoli; Alexis Brice; Robert J Smith
Journal:  Am J Hum Genet       Date:  2008-03-20       Impact factor: 11.025

10.  Variation in GIGYF2 is not associated with Parkinson disease.

Authors:  W C Nichols; D K Kissell; N Pankratz; M W Pauciulo; V E Elsaesser; K A Clark; C A Halter; A Rudolph; J Wojcieszek; R F Pfeiffer; T Foroud
Journal:  Neurology       Date:  2009-03-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.